TBIO Precipio Inc

Translate Bio to Participate in Upcoming Investor Conferences

Translate Bio to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the Company will participate in the following upcoming investor conferences:

  • Citi's 15th Annual BioPharma Virtual Conference: Frank DeRosa, Chief Technology Officer, will participate in a panel discussing COVID-19 vaccines on September 10, 2020, at 1:30 p.m. ET.
  • H.C. Wainwright 22nd Annual Global Investment Conference: John Schroer, Chief Financial Officer, will present a corporate overview on September 14, 2020, at 12:30 p.m. ET. 

A live webcast of the sessions will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcast will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead mRNA therapeutic program is being developed as a treatment for cystic fibrosis (CF) and is in a Phase 1/2 clinical trial. The Company is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur. The Company also believes its technology is applicable to a broad range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies for infectious disease and other diseases. For more information about the Company, please visit or on Twitter at @TranslateBio.

Contacts for Translate Bio

Investors Media
Teri Dahlman Maura Gavaghan
    
617-817-8655 617-233-1154

EN
03/09/2020

Underlying

TBIOPrecipio Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Precipio Inc

 PRESS RELEASE
Free
TBIO PRECIPIO INC

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company’s common stock to twenty new employees. These grants were made pursuant to the Company’s 2021 Inducement Stock Incen...

September 8, 2021 1 EN
 PRESS RELEASE
Free
TBIO PRECIPIO INC

Translate Bio Announces Second Quarter 2021 Financial Results and Prov...

Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update -- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA technology across vaccines and therapeutics development -- -- Advanced mRNA infectious disease vaccine programs, including Sanofi Pasteur initiation of influenza clinical trial; clinical trial results from two mRNA vaccines anticipated this year -- -- Continued progress in development of mRNA therapeut...

August 5, 2021 1 EN
 PRESS RELEASE
Free
TBIO PRECIPIO INC

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technolog...

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development -- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence -- -- Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology -- PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA)...

August 3, 2021 1 EN
 PRESS RELEASE
Free
TBIO PRECIPIO INC

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635...

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on July 6, 2021, the Company granted non-qualified stock options to purchase an aggregate of 177,400 shares of the Company’s common stock to nine new employees. These grants were made pursuant to the Company’s 2021 Inducement Stock...

July 7, 2021 1 EN
 PRESS RELEASE
Free
TBIO PRECIPIO INC

Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influ...

Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine -- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initiation of Phase 1 clinical trial -- -- Interim data anticipated by the end of 2021; outcomes from this clinical trial will inform next steps of our mRNA-based influenza vaccine program and strategy -- LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Sanofi...

June 22, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch